LOBO

Government of Canada celebrates successful outcomes at the International Commission for the Conservation of Atlantic Tunas meeting

Retrieved on: 
Friday, December 16, 2022

The Government of Canada works with domestic and international partners to manage fish stocks in a sustainable way that supports biodiversity and economic prosperity.

Key Points: 
  • The Government of Canada works with domestic and international partners to manage fish stocks in a sustainable way that supports biodiversity and economic prosperity.
  • The International Commission for the Conservation of Atlantic Tunas ( ICCAT ) met in Vale do Lobo, Portugal, from November14 to 21, 2022, its first in-person year-end meeting in three years.
  • The Canadian delegation comprised representatives from Fisheries and Oceans Canada, Global Affairs Canada, domestic stakeholders and Indigenous partners.
  • "I am really proud of the role Canada played at this year's meeting of the International Commission for the Conservation of Atlantic Tuna.

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Retrieved on: 
Friday, July 30, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. ("Lobo"), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoactive drugs.
  • In addition, Entheon issued an aggregate of 9,603 incentive stock options (the "Replacement Options") to the holders of the outstanding stock options of Lobo (the "Lobo Stock Options") in exchange for the cancellation of the Lobo Stock Options, and all outstanding common share purchase warrants in the capital of the Lobo were cancelled.
  • "With the acquisition of Lobo comes the addition of key staff members and enhanced expertise in the field of genetics.
  • Mr. Lem commented, "Lobo is pleased to officially join the Entheon team.

Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.

Retrieved on: 
Wednesday, June 16, 2021

Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company has entered into a definitive agreement dated June 15, 2021 (the "Agreement") with Lobo Genetics Inc. ("Lobo"), and 13089363 Canada Inc. ("Subco"), a wholly-owned subsidiary of Entheon.
  • "We are excited to join the Entheon team and leverage Lobo's existing genetics testing platform to future applications in the psychedelics space," said Chief Executive Officer of Lobo, John Lem.
  • Following the Transaction, the amalgamated company will be a wholly-owned subsidiary of the Company, under the name "Lobo Genetics Inc." ("Amalco") and carry on the business of Lobo.
  • Pursuant to the Agreement, in consideration for the common shares in the capital of Lobo (the "Lobo Shares"), the Company will issue an aggregate of 5,000,000 common shares (the "Consideration Shares") to the shareholders of Lobo.

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Retrieved on: 
Wednesday, February 24, 2021

Completion of research and development phase for HaluGen's Psychedelics Genetic Test

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. ("HaluGen"), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
  • In tandem with its research and development partner, Lobo Genetics Inc. ("Lobo"), HaluGen has successfully developed a turn-key operation to build, order, ship, process and deliver its Psychedelics Genetic Test.
  • HaluGen's technology platform also includes five pre-screening assessment surveys encompassing mental health, family history and lifestyle risk factors.
  • About HaluGen Life Sciences Inc.
    HaluGen has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk.